Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Maintains Neutral on PVH, Raises Price Target to $95

JP Morgan analyst Matthew Boss maintains PVH (NYSE:PVH) with a Neutral and raises the price target from $77 to $95.
byBenzinga Newsdesk
January 23, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Matthew Boss maintains PVH (NYSE:PVH) with a Neutral and raises the price target from $77 to $95.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AbbVie Receives Reimbursement Recommendation from Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for VENCLEXTA® (venetoclax) with azacitidine for Acute Myeloid Leukemia Pati…

By Michael Horton
Today, 10:42 PM
AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, announced today that the CADTH pCODR Expert Review Committee (pERC) recommends that VENCLEXTA® (venetoclax) in combination with azacitidine

ABBV